CSF3 and acute myeloid leukemia: A clinical trial by Bassan et al. (1998) showed that combination of carboplatin, granulocyte colony-stimulating factor, high-dose cytarabine on alternate days and mitoxantrone/idarubicin is well tolerated, and exerted a significant activity in high-risk AML (Bassan et al., 1998).